free ce

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this last episode of the 6-part series, an expert describes what is known about the SARS-CoV-2 variants—including the UK, South African, and Brazilian variants that are becoming more prevalent in the United States. The discussion then focuses on how these variants impact the efficacy of vaccines and monoclonal antibodies. Claim your credit at pce.is/COV19.

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.This episode provides an overview of the rapid development of vaccines currently under Emergency Use Authorization (EUA) for the prevention of SARS-CoV-2 in the United States. An expert describes the mechanisms of action for the mRNA and viral vector vaccines, as well as efficacy, side effects, and post-vaccine safety assessment. The conversation concludes with a review of what is needed to achieve herd immunity, and guidance for people who are fully vaccinated. Claim your credit at pce.is/COV19.

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this fourth episode of the 6-part series, an expert explains what COVID-19 treatments are available in the outpatient setting. The focus is on monoclonal antibodies, bamlanivimab + etesevimab and casirivimab + imdevimab. For both drug combinations, he discusses the Emergency Use Authorization (EUA) indications, evidence on efficacy, and potential toxicities. Claim your credit at pce.is/COV19.

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this second half of a discussion about treatments for COVID-19 in the hospital setting, an expert explains the use of dexamethasone, including insights on the choice of steroids to treat COVID-19 in pregnancy. The conversation then moves to other immune modulators, tocilizumab and the combination of baricitinib plus the antiviral remdesivir, and includes an overview of the evidence on efficacy and safety.Claim your credit at pce.is/COV19.

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.This episode is the first half of an expert discussion on treatments for COVID-19 in the hospital setting. The episode covers the latest information on the use of convalescent plasma and remdesivir, including the available efficacy data, when to administer treatment, and potential toxicities to expect.Claim your credit at pce.is/COV19.

In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox. This activity is available for CE/CME credit.

In this first of a 6-episode series on Emergency Use Authorization (EUA) in COVID-19, an expert explains the differences between EUA and full approval, how long EUAs last, and how new clinical trial evidence supports and changes an EUA. The discussion concludes with an overview of safety and management of potential adverse events. Claim your credit at pce.is/COV19.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now firmly established as guideline-recommended antiglycemic agents of choice in patients with type 2 diabetes, especially when comorbid disease is evident or when the patient is at high risk for such conditions. Join Davida Kruger, NP and Anne Peters, MD for a lively discussion on the use of GLP-1 RAs in clinical practice, including how to use shared decision-making to choose an ideal agent based on patient, disease, and GLP-1 RA characteristics. The unique effects of GLP-1 RAs on cardiovascular disease and weight mitigation are also discussed in the context of patient selection and management.

This episode is available for CE/CME credit.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now firmly established as guideline-recommended antiglycemic agents of choice in patients with type 2 diabetes, especially when comorbid disease is evident or when the patient is at high risk for such conditions. In this second of two podcasts, Davida Kruger, NP and Anne Peters, MD share tips and pearls for treating patients with type 2 diabetes using GLP-1 RAs, including when to choose a GLP-1 RA, how to broach the topic of a first injectable, when an oral agent is preferred, strategies for encouraging lifestyle modifications, and practical advice on preparing and monitoring patients with respect to GLP1-RA therapy.

This episode is available for CE/CME credit.

Follow CEimpact on Social Media:
LinkedIn
Instagram